Company / Cost of Revenue
BioNexus Gene Lab Corp Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.3M
FY2025
5-year range
$6.3M / $11.1M
FY2021-FY2025
Trend
-22.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 4 consecutive years, from $11M in FY2021 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -8.1%.
Improved from $8M to $6M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- -8.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- BioNexus Gene Lab Corp's cost of revenue has declined for 4 consecutive years.
- 5-year CAGR of -8.1%, indicating a declining trend.
- In FY2025, cost of revenue decreased 22.9% year-over-year.
- Peak cost of revenue was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.3M | -22.9% |
| FY2024 | $8.2M | -2.6% |
| FY2023 | $8.4M | -12.7% |
| FY2022 | $9.7M | -12.9% |
| FY2021 | $11.1M | +14.7% |
| FY2020 | $9.7M | +13507.7% |
| FY2019 | $71.1K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026